TNF抑制剂起始时抑郁焦虑症状与中轴型脊柱关节炎治疗反应受损相关
研究基于国家中轴型脊柱关节炎注册队列中742例 biologic naïve 参与者,在启动TNF抑制剂前完成HADS评估,采用边际结构模型分析基线抑郁焦虑症状与BASDAI、ASDAS变化及停药时间的关联。结果显示中重度抑郁和焦虑症状与更差的治疗反应及更高的停药风险相关。
要点
- 中重度抑郁症状者随访期间BASDAI和ASDAS改善显著差于无症状者。
- 中重度焦虑症状者6个月时BASDAI差约1.7、ASDAS差约0.7个单位。
- 中重度焦虑者治疗停药风险为无症状者的1.59倍(HR 95%CI 1.12, 2.26)。
核心结论
- TNF抑制剂启动时的抑郁和焦虑症状与中轴型脊柱关节炎患者更差的治疗结局相关。
- 针对心理健康的干预有潜力改善治疗反应和持续性。
研究设计与样本
- 来自国家中轴型脊柱关节炎注册的biologic naïve参与者,在启动TNF抑制剂前完成医院焦虑抑郁量表(HADS)。
- 共纳入742例参与者,67%为男性,平均年龄45岁。
- 采用边际结构模型分析,并用逆概率权重平衡基线年龄、性别、BMI、剥夺指数、教育程度及各自疾病指数的基线值。
主要发现
- 176例(24%)有中重度抑郁,26%有轻度抑郁;295例(40%)有中重度焦虑,23%有轻度焦虑。
- 抑郁和焦虑的HADS症状类别越高,基线疾病活动度越高。
- 中重度抑郁者随访期间治疗反应显著差于无症状者,6个月时BASDAI差约2.2、ASDAS差约0.8个单位(平衡基线值后)。
- 焦虑的等效比较为BASDAI差1.7、ASDAS差0.7个单位。
- 中重度焦虑者治疗停药风险为无症状者的1.59倍(HR 95%CI 1.12, 2.26)。
关键数值与推荐
- HADS焦虑和抑郁症状分别 categorised 为中重度(≥11)、轻度(8-10)和无(≤7)。
- 中重度抑郁6个月时BASDAI差约2.2、ASDAS差约0.8个单位;中重度焦虑BASDAI差1.7、ASDAS差0.7个单位。
- 中重度焦虑停药HR 1.59(95%CI 1.12, 2.26),对比无症状。
临床怎么用
- 在启动TNF抑制剂前评估中轴型脊柱关节炎患者的抑郁和焦虑症状,有助于识别治疗反应可能较差者。
- 对中重度抑郁或焦虑症状者考虑针对性心理干预,可能改善治疗反应和用药持续性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Depression and anxiety are associated with more severe disease in cross-sectional studies of axial spondyloarthritis (axSpA). We examined the association between baseline symptoms of depression or anxiety and response to TNF inhibitors (TNFi) in axSpA. METHODS: Biologic naïve participants from a national axSpA register completed the Hospital Anxiety and Depression Scale (HADS) before initiating TNFi. Symptoms of anxiety and depression were each categorized as moderate-severe (≥11), mild (8-10) and 'none' (≤7), and compared against change in disease indices [BASDAI and AS Disease Activity Score (ASDAS)] over time and time to treatment discontinuation using marginal structural models. Inverse-probability weights balanced baseline age, gender, BMI, deprivation, education and baseline values of respective disease indices. RESULTS: Of the 742 participants (67% male, mean age 45 years), 176 (24%) had moderate-severe and 26% mild depression; 295 (40%) had moderate-severe and 23% mild anxiety. Baseline disease activity was higher in higher HADS symptom categories for both depression and anxiety. Participants with moderate-severe depression had significantly poorer response compared with those with 'none' throughout follow-up. At 6 months, the difference was approximately 2.2 BASDAI and 0.8 ASDAS units after balancing their baseline values. Equivalent comparisons for anxiety were 1.7 BASDAI and 0.7 ASDAS units. Treatment discontinuation was 1.59-fold higher (hazard ratio 95% CI: 1.12, 2.26) in participants with moderate-severe anxiety compared with 'none'. CONCLUSIONS: Symptoms of depression and anxiety at TNFi initiation are associated with poorer treatment outcomes. Targeted interventions to optimize mental health have potential to substantially improve treatment response and persistence.
引用
- Zhao SS, Jones GT, Hughes DM, et al. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology (Oxford). 2021. PMID: 33713118. doi:10.1093/rheumatology/keab242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。